Menu
← Company library
Japan / Company briefSources checked 2026-10-03

武田薬品工業株式会社

Takeda

An R&D-driven biopharmaceutical company engaged in pharmaceutical research, manufacturing, sales and international trade.

01

Products & pipeline

ORZEYFUL / oveporexton

Approved

Announced FDA approval for adults with narcolepsy type 1; availability was stated to follow DEA scheduling.

As of 2026-08-05Market USTakeda ↗
02

Recent developments

Completion reported

Announced US approval of oral orexin 2 receptor agonist ORZEYFUL.

Takeda ↗
03

Experience in official career sources

Recruitment program

2027年入社 研究技術職

Current availability unconfirmed

Observed 2026-10-03 · Application window 2026-07-27 — Date unconfirmed

Work
Unconfirmed — Detailed requirements were not confirmed in the reviewed official material.
Experience & requirements
Unconfirmed — Detailed requirements were not confirmed in the reviewed official material.
Official source ↗
Sources & coverage 3

A brief based on selected official material, not an exhaustive product or vacancy list.

  1. 会社概要 ↗武田薬品 · Published Date unconfirmed · Sources checked 2026-10-03
  2. ORZEYFUL approved for narcolepsy type 1 ↗Takeda · Published 2026-08-05 · Sources checked 2026-10-03
  3. 採用情報 ↗武田薬品 · Published Date unconfirmed · Sources checked 2026-10-03